Every 8-K that DaVita Inc. (DVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DVA filings page.
DaVita Inc. reported strong results for the quarter ended June 30, 2026, with consolidated revenues of $3.554 billion, operating income of $579 million and diluted EPS of $4.02. Net income attributable to DaVita Inc. was $265 million. Operating margin improved to 16.3% from 14.1% in the prior quarter. Operating cash flow reached $490 million and free cash flow was $256 million.
U.S. dialysis volume totaled 7,226,600 treatments, or 92,649 per day, with normalized non‑acquired treatment growth of 0.3% versus the prior year’s quarter. The company served about 298,500 patients at 3,266 outpatient centers worldwide and had roughly 64,900 patients in risk‑based integrated kidney care arrangements representing $5.8 billion of annualized medical spend. DaVita added a $500 million Term Loan B‑2 tranche, ending the period with total debt of $10.848 billion and a leverage ratio of 3.37x, and repurchased 2.2 million shares for $348 million. For 2026, it forecasts adjusted operating income of $2.15–$2.25 billion, adjusted diluted EPS of $14.10–$15.20 and free cash flow of $1.0–$1.25 billion.
DaVita Inc. entered into a Ninth Amendment to its 2019 Credit Agreement, adding an incremental $500 million in senior secured Tranche B-2 Term Loans maturing in May 2031. These loans are in U.S. dollars and bear interest at either a Base Rate plus a 75-basis-point applicable margin or Term SOFR plus a 175-basis-point applicable margin.
DaVita has used or will use the new term loan proceeds to repay a portion of its senior secured revolving loan facility terminating in November 2030, pay related fees and expenses, and for general corporate purposes. At its virtual 2026 annual meeting, stockholders representing 59,865,902 shares, about 91% of shares outstanding as of April 9, 2026, elected nine directors, ratified KPMG LLP as auditor for 2026, and approved named executive officer compensation on an advisory basis.
DaVita Inc. reported solid results for the quarter ended March 31, 2026, with consolidated revenues of $3.416 billion and operating income of $482 million, reflecting a higher operating margin of 14.1% versus 13.6% a year earlier.
Net income attributable to DaVita was $197.5 million, or $2.87 in diluted earnings per share from continuing operations, up from $2.00 a year ago. Operating cash flow rose to $321 million, and free cash flow improved to $140 million from a negative $45 million in the prior-year quarter.
U.S. dialysis treatment volume was 7.03 million, with average patient service revenue per treatment of $417.59. The company was serving about 296,300 patients at 3,262 centers worldwide and had roughly 62,600 patients in risk-based integrated kidney care arrangements representing $5.4 billion in annualized medical spend.
DaVita continued returning capital, repurchasing 3.0 million shares for $403 million in the quarter and another 2.0 million shares for $302 million through May 5, 2026. Management reaffirmed 2026 free cash flow guidance and modestly raised ranges for adjusted operating income and adjusted diluted EPS.
DaVita Inc. filed a current report to announce that it has issued a press release with its financial results for the quarter ended December 31, 2025. The company furnished this earnings release as an exhibit rather than filing it, which limits how it is treated under securities laws.
The report identifies the press release as Exhibit 99.1 and confirms that DaVita’s common stock continues to trade on the New York Stock Exchange under the symbol DVA.
DaVita Inc. entered into an Eighth Amendment to its existing Credit Agreement, adding a new five-year secured term loan A facility of up to $2 billion and a new five-year secured revolving credit facility of up to $1.5 billion. These new facilities are designed to refinance amounts outstanding under the company’s prior term loan A and revolving credit facilities that were scheduled to mature in April 2028.
Borrowings can be made in U.S. dollars, euros, or pounds sterling, with interest based on benchmark rates such as Term SOFR, EURIBOR, or Daily Simple SONIA plus an Applicable Margin. The initial margin is 150 basis points for benchmark-based loans and 50 basis points for Base Rate loans, with both the margin and the undrawn commitment fee later tied to a leverage ratio grid after financial statements for the quarter ending March 31, 2026 are delivered. The new term loan amortizes quarterly starting March 31, 2026, and proceeds are allocated to repay the prior facilities, pay related fees and expenses, and support working capital and general corporate purposes, including potential stock repurchases, acquisitions, and investments.
DaVita Inc. furnished an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information is being furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth. Additional materials include Exhibit 104.0 for the cover page Inline XBRL tags.
DaVita Inc. reported that its board of directors has increased the authorization under its existing share repurchase program by an additional $2,000,000,000. This new repurchase authority is in addition to the amount remaining under the share repurchase program originally authorized on September 5, 2024, and it has no expiration date.
The company is not obligated to buy back any shares and may conduct repurchases in the open market or through privately negotiated transactions, including under its share repurchase agreement dated April 30, 2024 with Berkshire Hathaway Inc., as well as through accelerated share repurchases, derivatives, tender offers or Rule 10b5-1 plans. The timing and size of any repurchases will depend on market conditions, legal and contractual limits, and other factors, and DaVita can modify, suspend or discontinue the program at any time.